Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LXRX | US
0.08
4.97%
Healthcare
Biotechnology
30/06/2024
04/10/2024
1.69
1.63
1.71
1.62
Lexicon Pharmaceuticals Inc. a biopharmaceutical company focuses on the discovery development and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211 which is in Phase II clinical development for the treatment of neuropathic pain and LX2761 which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech Inc. The company was incorporated in 1995 and is headquartered in The Woodlands Texas.
View LessStrength based on increasing price with high volume
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
50.9%1 month
41.2%3 months
83.7%6 months
74.9%-
-
2.41
0.44
0.28
-2.58
101.41
-0.14
-196.47M
610.92M
610.92M
-
-3.36K
-63.40
419.60
-94.81
11.00
16.34
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.22
Range1M
0.27
Range3M
0.96
Rel. volume
1.22
Price X volume
5.01M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ATXS | ATXS | Biotechnology | 11.87 | 669.77M | 2.06% | n/a | 1.67% |
ANNX | ANNX | Biotechnology | 6.29 | 664.56M | -2.02% | n/a | 8.36% |
OLMA | OLMA | Biotechnology | 11.6 | 664.29M | -3.73% | n/a | 0.86% |
Humacyte Inc | HUMA | Biotechnology | 5.44 | 650.86M | -4.39% | n/a | -63.37% |
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 23.88 | 645.77M | -6.28% | n/a | 11.94% |
Entrada Therapeutics Inc. Common Stock | TRDA | Biotechnology | 17.07 | 635.00M | 4.79% | 5.45 | 14.99% |
Y-Mabs Therapeutics Inc - Ordinary Shares | YMAB | Biotechnology | 14.16 | 631.11M | 0.57% | n/a | 1.34% |
Savara Inc | SVRA | Biotechnology | 3.82 | 628.78M | -2.05% | n/a | 26.18% |
Stoke Therapeutics Inc | STOK | Biotechnology | 11.79 | 620.72M | -3.28% | n/a | 2.40% |
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.42 | 593.84M | 0.95% | n/a | 50.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.58 | 0.76 | Cheaper |
Ent. to Revenue | 101.41 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.41 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 83.65 | 74.67 | Par |
Debt to Equity | 0.44 | -1.82 | Expensive |
Debt to Assets | 0.28 | 0.26 | Par |
Market Cap | 610.92M | 3.73B | Emerging |